345 related articles for article (PubMed ID: 22820319)
61. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha I; McKoy N
Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
[TBL] [Abstract][Full Text] [Related]
62. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.
Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS
Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234
[TBL] [Abstract][Full Text] [Related]
63. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
64. Soluble CD14 as a predictor of subsequent development of recurrent wheezing in hospitalized young children with respiratory syncytial virus-induced bronchiolitis.
Soferman R; Bar-Zohar D; Jurgenson U; Fireman E
Ann Allergy Asthma Immunol; 2004 May; 92(5):545-8. PubMed ID: 15191023
[TBL] [Abstract][Full Text] [Related]
65. Effectiveness of palivizumab prophylaxis in infants and children in Florida.
Winterstein AG; Hampp C; Saidi A
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):53-60. PubMed ID: 21919115
[TBL] [Abstract][Full Text] [Related]
66. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
[TBL] [Abstract][Full Text] [Related]
67. Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial.
Kneyber MC; van Woensel JB; Uijtendaal E; Uiterwaal CS; Kimpen JL;
Pediatr Pulmonol; 2008 Feb; 43(2):142-9. PubMed ID: 18085694
[TBL] [Abstract][Full Text] [Related]
68. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab.
Resch B; Michel-Behnke I
Curr Opin Cardiol; 2013 Mar; 28(2):85-91. PubMed ID: 23337892
[TBL] [Abstract][Full Text] [Related]
69. Respiratory syncytial virus infection and recurrent wheezing: what next?
Puddu M; Fanos V
J Chemother; 2007 Oct; 19 Suppl 2():8-11. PubMed ID: 18073170
[TBL] [Abstract][Full Text] [Related]
70. RSV immunoprophylaxis: does the benefit justify the cost?
Meissner HC; Kimberlin DW
Pediatrics; 2013 Nov; 132(5):915-8. PubMed ID: 24127478
[No Abstract] [Full Text] [Related]
71. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
[TBL] [Abstract][Full Text] [Related]
72. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.
Carbonell-Estrany X; Bont L; Doering G; Gouyon JB; Lanari M
Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):891-9. PubMed ID: 18629558
[TBL] [Abstract][Full Text] [Related]
73. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
[TBL] [Abstract][Full Text] [Related]
74. Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis.
Brunwasser SM; Snyder BM; Driscoll AJ; Fell DB; Savitz DA; Feikin DR; Skidmore B; Bhat N; Bont LJ; Dupont WD; Wu P; Gebretsadik T; Holt PG; Zar HJ; Ortiz JR; Hartert TV
Lancet Respir Med; 2020 Aug; 8(8):795-806. PubMed ID: 32763206
[TBL] [Abstract][Full Text] [Related]
75. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
Bernard L; Lecomte B; Pereira B; Proux A; Boyer A; Sautou V
Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
[TBL] [Abstract][Full Text] [Related]
76. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
Zamora MR; Budev M; Rolfe M; Gottlieb J; Humar A; Devincenzo J; Vaishnaw A; Cehelsky J; Albert G; Nochur S; Gollob JA; Glanville AR
Am J Respir Crit Care Med; 2011 Feb; 183(4):531-8. PubMed ID: 20851929
[TBL] [Abstract][Full Text] [Related]
77. Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study.
Kato M; Mochizuki H; Kama Y; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Pediatr Pulmonol; 2024 Mar; 59(3):743-749. PubMed ID: 38116923
[TBL] [Abstract][Full Text] [Related]
78. Monocyte IL-10 production during respiratory syncytial virus bronchiolitis is associated with recurrent wheezing in a one-year follow-up study.
Bont L; Heijnen CJ; Kavelaars A; van Aalderen WM; Brus F; Draaisma JT; Geelen SM; Kimpen JL
Am J Respir Crit Care Med; 2000 May; 161(5):1518-23. PubMed ID: 10806148
[TBL] [Abstract][Full Text] [Related]
79. Palivizumab in infants with gestational age < or = 28 weeks and bronchopulmonary dysplasia.
Parmigiani S; Ubaldi A; Capuano C; Massinissa Magini G; Bianchi ME
Acta Biomed Ateneo Parmense; 2001; 72(5-6):109-13. PubMed ID: 12233268
[TBL] [Abstract][Full Text] [Related]
80. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
